Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)
China flag China · Delayed Price · Currency is CNY
5.75
-0.15 (-2.54%)
Sep 10, 2026, 12:44 PM CST

Beijing SL Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-724.05-347.2-74.07416.69234.4425.94
Depreciation & Amortization
167.12166.77152.96145.4113.8899.8
Other Amortization
0.290.290.280.280.170.17
Loss (Gain) From Sale of Assets
0.050.05---0.21-3.22
Asset Writedown & Restructuring Costs
-22.37-338.17172.29-0.0100.02
Loss (Gain) From Sale of Investments
110.43-2.34-13.13-239.47-98.13-209.01
Provision & Write-off of Bad Debts
-0.38--23.8131.9426.25
Other Operating Activities
0.2-0.23-0.661.05-5.99-4.38
Change in Accounts Receivable
50.61-14.7662.4519.6682.88108.64
Change in Inventory
273.08-436.26-102.33-4.250.58-11.5
Change in Accounts Payable
77.28544.6868.5166.5836.5617.54
Change in Other Net Operating Assets
621.15621.1511.09---
Operating Cash Flow
558.39257.66225.49460.2389.82464.63
Operating Cash Flow Growth
3128.06%14.27%-51.00%18.05%-16.10%11.73%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-64.56-192.97-347.38-218.36-163.49-236.91
Sale of Property, Plant & Equipment
0000.011.477.49
Divestitures
-----4.88-
Investment in Securities
-73.626.4-33.46-86.95-384.76-0.96
Other Investing Activities
34.1727.29169.29-39.3511.2532.55
Investing Cash Flow
-103.99-139.28-211.55-344.65-540.4-197.82

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
-----5.5
Total Debt Issued
-----5.5
Short-Term Debt Repaid
------14.5
Long-Term Debt Repaid
------0.4
Lease Payments
------0.4
Total Debt Repaid
------14.9
Net Debt Issued (Repaid)
------9.4
Common Dividends Paid
-17.9-17.9-154.1-102.74-102.74-102.93
Other Financing Activities
-----9
Financing Cash Flow
-17.9-17.9-154.1-102.74-102.74-103.33

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-00-00.030.1-0.02
Net Cash Flow
436.5100.49-140.1712.84-253.21163.45

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
493.8364.69-121.89241.84226.33227.72
Free Cash Flow Growth
---6.85%-0.61%42.42%
Free Cash Flow Margin
86.60%10.37%-18.46%23.75%21.55%18.75%
Free Cash Flow Per Share
0.480.06-0.120.240.220.22
Levered Free Cash Flow
400.43-36.59-260.4186.77121.34113.97
Unlevered Free Cash Flow
400.43-36.59-260.4186.77121.4114.11
Free Cash Flow After Leases
493.8364.69-121.89241.84226.33227.32

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
41.9726.639.1488.1691.5585.63
Change in Working Capital
1,027778.49-12.18112.45113.75129.06